

Investor Presentation August 2024



FORWARD LOOKING STATEMENTS


This presentation has been prepared by Movano Inc. dba Movano Health ("we," "us," "our," "Movano" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither this presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding plans with respect to the commercial launches of the Evie Ring and EvieMED; our expectations regarding potential commercial opportunities; planned cost cutting initiatives; anticipated FDA clearance decisions with respect to our products; expected future operating results; product development efforts and product releases; clinical trial and regulatory initiatives; commercial partner activities; as well as our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.



STATEGIC MILESTONES – 18 MONTHS






*The Company submitted for 510(k) clearance of the EvieMED Ring in April 2024. Timing is subject to regulatory review and approval.



NEWS AND UPDATES – AUGUST 2024



.....



- Announced 9.17.24 Evie Ring back in stock date.
- Announced brand partnership with influencer and digital creator Heidi D'Amelio.
- Product, operations and customer service enhancements should bolster September expanded launch.

- Announced live planned meeting with the FDA to move the review process forward for 510(k) clearance of EvieMED Ring.
- Important progress made with three additional B2B commercial opportunities that could leverage EvieMED – two global pharmaceutical companies and a large payor.

- In June 2024, Movano Health completed a cuffless blood pressure clinical study that included the use of an arterial blood pressure line.
- The Company plans to execute another cuffless blood pressure clinical study in the fourth quarter of 2024 with a smaller, more commercially viable device.




D2C BUSINESS DRIVERS

BRAND AMBASSADOR HEIDI D'AMELIO	INFLUENCER AND UGC CAMPAIGN	MEDIA BLITZ	CUSTOMER ENGAGEMENT AND OUTREACH
<text></text>	<image/>	Tech and Consumer Press Satellite Tour	150K Lead List
		Updated Reviews	Back in Stock Campaign
		Holiday Gift Guides	Newsletter Series / Ongoing Blog Content
		<image/>	<complex-block></complex-block>




D2C BUSINESS DRIVERS






WEARABLE MARKET GROWING EXPONENTIALLY





EVIE'S JOURNEY





THE EVIE RING FILLS A UNIQUE NEED NOT CURRENTLY ADDRESSED

.....

WOMEN-FOCUS

NO EXISTING SOLUTION

- Form factor and sizing designed for women
- Personalized insights derived from AI
- Gamify the process of getting healthier
- Menstrual health prioritized for all stages
- Mental health correlated with passivelycollected ring data
- Medical grade technology

ENTERPRISE

NO EXISTING SOLUTION

- Pharma needs a medical-grade device for clinical trials and post-market surveillance
- Medical device companies need patient status for real-time optimization
- Payors need medical-grade Remote Patient Monitoring (RPM) capabilities
- Retailers are looking for health narrative



uniquely positioned to satisfy these market needs

FITNESS & WELLNESS

INCUMBENT PRODUCTS ARE ONE-SIZE-FITS-ALL

- Serve fitness enthusiasts
- Focus on comms, staying connected
- Quantitatively track performance metrics
- Bring awareness to sleep duration and stages



GARMIN

ŌURA



WOMEN'S HEALTH FOCUS: IT'S ABOUT TIME

\$44B 2023 US Market Size: Women's Health¹


\$100M White House Investment in Women's Health²

1000+Women interviewed to design Evie

 <u>https://www.grandviewresearch.com/industry-analysis/womens-health-market</u>
 <u>https://www.whitehouse.gov/briefing-room/speeches-remarks/2024/02/21/remarks-as-prepared-for-delivery-by-first-</u> lady-jill-biden-to-announce-the-100-million-arpa-h-sprint-for-womens-health/



EVIE US MARKET TAM & COMPOSITION





KEY EVIE RING DIFFERENTIATORS

.....

Sleek, Smart, Comfortable Hardware

- Open ring design offers comfortable fit
- Rated most aesthetically pleasing smart ring (Wall Street Journal)
- Compact, portable recharging case




Novel App Design

- Seamlessly tracks key biometric data including menstrual cycle, mood, energy
- Personalized activity and performance goals
- Industry first Daily Summary dynamically displays daily progress

3

Al-Driven Insights

• Identifies correlations, patterns and trends across different vital signs, menstrual health, mood, energy, sleep and activity in longitudinal data



Balancing rest and RHR

Hello Stacy, we've noticed a bit of a pattern: you've been getting less sleep and have had a slight increase in your resting heart rate (RHR). This link between less sleep and elevated RHR is a natural reaction—in fact, it's your body signaling a need for more downtime.

We know getting enough sleep can be challenging, but when you can, aim to catch up on your rest. While many people wind down by watching TV or browsing social media, being exposed to screens can actually be quite detrimental in preparing your body for good sleep.The American Heart Association recommends choosing calming pre-sleep activities, away from digital distractions. But if you must check your devices, they suggests dimming your screens.







EVIE APP INSIGHTS EXPERIENCE


.....

Passively collected body data on sleep





Educational insight based on her experience





HOW EVIE RING STACKS UP





*Fitbit, Whoop, and Oura devices make nighttime readings only.




EVIE MED: STRONG B2B PROPOSITION

.....






THE FIRST SMART RING TO FILE FOR FDA CLEARANCE ON SpO_2 & HR



1. Arterial blood gas used as reference, 2. Nellcor OxiMax N-595 used as reference




MOVANO HEALTH'S B2B OPPORTUNITY






CURRENT B2B ENGAGEMENTS ACROSS THE HEALTHCARE CONTINUUM

.....






USE CASE #1 - Pharmaceutical Companies





USE CASE #2 - Payors





USE CASE #3 - Remote Patient Monitoring (RPM)



- Increasing needs to monitor patients remotely, due to broad lifestyle shifts and preferences
- In-office visits involve high cancellations; higher costs for patients and slower throughput for physicians
- Reduced frequency of physician monitoring promote suboptimal health monitoring
- Regular monitoring reduce costs of healthcare
 - Any device or component of an RPM solution must be FDA approved/cleared
 - Improves access to healthcare (for patients of limited means, rural areas, complex needs, etc.)

TRACTION

GROWTH

PROBLEM

SOLUTION

- "Leading US RPM company" Beta II partner
- "Leading US RPM company" serves >450 healthcare organizations and is the exclusive platform for one of the largest medical device companies in the world

• 2 near-term RPM customers in pipeline



÷

USE CASE #4 - Medical Device Patient Management



- Inability to continuously monitor patients outside physician's office
- Suboptimal patient outcomes
- In-person monitoring is expensive
- Ability to make real-time adjustments to patient regiment, improving outcomes
- Continuous data feed provides physicians better intelligence
- Reduces friction and cost to delivery patient care

TRACTION

PROBLEM

SOLUTION

- "Leading med device company" has engaged in initial draft of LOI
- "Leading med device company" serves >200k new patients/devices per year

GROWTH

• 5 near-term medical device customers in pipeline



MEDICAL DEVICE POSITIONING CREATES SIGNIFICANT BARRIERS TO ENTRY IN ENTERPRISE MARKET

To Compete With Movano Health, Companies Would Have To...

1

Create Medical Device Infrastructure

- Implement a Quality Management System (QMS)
- Hire medical device personnel for Quality, Regulatory, and Clinical (QRC)
- Train every employee on Standard Operating Procedures

Pursue FDA Clearance

- Establish clinical trials, generate all required documents
- Set up production to comply with FDA Good Manufacturing Practices

3

2

Establish Post Market Surveillance Functions

• Ongoing QRC initiatives to track product, complaints, CAPAs

Transitioning an existing wearables operation into a medical device company would be **extremely costly** and take **several years to execute**




MATERIAL PROGRESS WITH PROPRIETARY AND PATENTED RF TECHNOLOGY

.....






BREAKTHROUGH IN BLOOD PRESSURE MONITORING WITH CLINICAL RESULTS IN LINE WITH AN FDA RECOGNIZED STANDARD



- Cuffless wrist worn device
- Clinical study in 43 subjects
- BP measurements at rest and under stress



Movano BP prediction

¹ Mean Absolute Difference (MAD) required per IEEE 708a-2019 standard for wearable, cuffless blood pressure measuring devices

² Company's algorithm for blood pressure monitoring utilized data from its prototype system combined with the subject's demographic information and

a recent blood pressure reading

Movano Health patent summary

US: 30 Issued, 14 Pending (1 allowed)

Foreign: 2 Issued (China/Europe), 3 Pending (1 China/2 Europe) PCT: 1 Pending

KEY US PATENTS FALL INTO FOUR CATEGORIES

RF IC Architecture

(2) Issued

Covers RF IC design, including multi-band mixing and conductor loss mitigation that is critical at high frequencies.

Key Issued Patents:

•Systems for multi-band radar-based sensing (US 11,298,037) •Methods for multi-band radar-based sensing (US 10,874,314)

Ring

(3) Pending

Covers various aspects of the current Evie Ring and charger design, including the 2-piece open-ended construction, production efficiencies, and control efficiencies.

Pending Patents:

Finger wearable health monitoring device
Finger wearable devices and methods for producing finger wearable devices
Ring charging case

RF-Based Health Monitoring

(25) Issued (5) Pending

Covers signal processing techniques for generating high resolution pulse wave signal to determine HR, BP, BG level.

Key Issued Patents:

•Systems for RF-based health monitoring utilizing amplitude and phase data (US 11,445,929)

•Methods and systems for monitoring BP using stepped frequency radar with spectral agility (US 11,360,188)

•System for monitoring a physiological parameter that involves coherently combining data from RF-based sensor system (US 11,883,132)

•System for monitoring a health parameter of a person utilizing a pulse wave signal (US 11,786,133)

Machine Learning Applications

(3) Issued (6) Pending

Techniques for generating training data and training ML models for health monitoring, and techniques for utilizing ML models for health monitoring, including blood pressure and blood glucose.

Key Issued Patents:


•Methods for training a model for use in RF-based health monitoring (US 11,464,419)

•Methods for training a model for use in radio waved based blood pressure monitoring (US 11,596,321)



CORPORATE SNAPSHOT (NASDAQ: MOVE)

.



* The Company is party to an At the Market Issuance Agreement with JonesTrading Institutional Services LLC. Pursuant to the terms of the Issuance Agreement, the Company may sell from time to time through the Sales Agent shares of the Company's common stock having an aggregate offering price of up to \$50M.



NASDAQ: MOVE

+1 (415) 651-3172

6800 Koll Center Pkwy. Pleasanton, CA 94566

www.movanohealth.com www.eviering.com

